CSF1R and breast cancer: In murine BC models, the inhibition of CSF1/CSF1R signaling through either CSF1 monoclonal antibodies or the CSF1R tyrosine kinase inhibitor PLX3397 results in the depletion of TAMs and significantly postpones tumor recurrence following radiotherapy (74).